Urinary prostaglandin and prostaglandin metabolite excretion in patients with essential hypertension or hypertension with renal artery stenosis

C.T. Postma a,*, Th. de Boo b, C.M.G. Thomas c, Th. Thien a

a Department of Medicine, Division of General Internal Medicine, University Hospital, PO Box 9101, 6500 HB Nijmegen, Netherlands
b Department of Medical Statistics, University Hospital, Nijmegen, Netherlands
c Laboratory of Gynecology and Obstetrics, University Hospital, Nijmegen, Netherlands

Received 14 February 1995; revision received 18 April 1995; accepted 31 May 1995

Abstract

Background: Recent studies have reported elevated prostaglandin levels in patients with renal artery stenosis and hypertension. To investigate whether a distinction between essential hypertension and hypertension with renal artery stenosis is possible by measuring eicosanoid excretion, we studied the excretion of these compounds in patients with essential hypertension and in hypertensives with concomitant renal artery stenosis.

Methods: The 24-h urinary excretion of metabolites of prostaglandin I 2, prostaglandin E 2 and metabolites of thromboxane A 2 was sampled under standardised conditions, in 15 patients with essential hypertension and in 15 patients with unilateral renal artery stenosis with hypertension. Also clinical and biochemical characteristics of the subjects were analysed.

Results: The patients with renal artery stenosis had significantly lower excretion of prostaglandin I 2 than did the essential hypertensive patients. However, the overlap in the values was large, thus not allowing a diagnostic differentiation according to urinary prostaglandin I 2 levels. The excretion of prostaglandin E 2 and of metabolites of thromboxane A 2 showed no significant differences among the groups.

Conclusions: Measurement of urinary prostaglandin or prostaglandin metabolite excretion did not contribute to the non-invasive detection of the presence of a renal artery stenosis in the patients in this study.

Keywords: Hypertension; Renal artery stenosis; Urinary prostaglandin excretion

1. Introduction

Prostaglandin endoperoxides are constituents of the renal regulatory mechanism of angiotensin-induced hypertension, both in the animal model and in humans [1–4]. In animal studies it was shown that in renin–angiotensin-dependent hypertension the levels of plasma 6-ketoprostaglandin F 1α, a stable metabolite of prostaglandin I 2 (PGI 2), and thromboxane B 2 (PGB 2), a stable metabolite of thromboxane A 2 (PGA 2), are elevated and that also urinary excretion of 6-keto-
Recent studies in humans have revealed that in subjects with renal artery stenosis, systemic plasma levels of prostaglandin E₂ (PGE₂) are higher than in patients with essential hypertension and that the renal vein plasma levels of PGE₂ are higher on the stenotic side than on the non-stenotic side [3,4]. Also levels of PGI₂ and of PGA₂ were shown to be elevated in renal artery stenosis in humans [5–9].

The prostaglandins have a predominantly vasodilator effect at the level of the afferent glomerular arteriole [10,11]. The intrarenal effects of the renin-angiotensin system are mainly confined to the efferent arteriole and exert a vasoconstrictor effect through angiotensin II, whose effects are partly mediated via the vasoconstrictive activity of PGA₂ [1,10]. These microcirculatory changes act to preserve glomerular filtration fraction in states of impaired renal perfusion pressure [8,13]. If renal perfusion pressure declines, PGI₂ production in the endothelial cells of the vas afferens rises [7]. The PGI₂ in turn potentiates renin release by the juxtaglomerular apparatus [12,14].

Recent experiments have confirmed the importance of the mechanisms described in renal artery stenosis (RAS) in humans [3,4,8,15,16]. Intravenous aspirin lowered PGE₂ and renin concentrations, in the human renal vein from the kidney distal to an unilateral RAS, with concomitant lowering of the blood pressure [3]. A significant decline in PGE₂ and renin concentrations, after the administration of aspirin, was also reported in the renal veins distal to a unilateral RAS, in patients in whom blood pressure was cured or improved after percutaneous transluminal renal angioplasty, but not in patients in whom blood pressure did not improve after the relief of a renal artery stenosis [4]. Thus, by inhibiting PGE₂ production, renin production was attenuated and blood pressure fell, at least in the acute experiments [3,4].

On the basis of these experiments it can be assumed that in renovascular hypertension the renal production of PGE₂, PGI₂ and PGA₂ is increased [2–4]. In essential hypertension the eicosanoids do not seem to participate directly in the control of arterial pressure and their levels have not been shown to be raised [8,17]. Thus, by measuring renal prostaglandin production it might be possible to differentiate between essential hypertension and hypertension with a unilateral RAS.

The least invasive and most reliable way of assessing intrarenal prostaglandin production is to measure the urinary excretion of PGE₂, 6-ketoprostaglandin F₁α, and PGB₂ [18]. Only a slight day-to-day variation in the excretion of PGE₂ has been reported [19]. We measured the 24-h urinary excretion of these eicosanoids in patients with essential hypertension and in patients with unilateral renal artery stenosis and hypertension, to examine whether the assumed differences in urinary prostaglandin excretion would be apparent.

### 2. Patients and methods

Included in the study were 15 patients with essential hypertension and 15 patients with hypertension and a unilateral renal artery stenosis. Hypertension was defined as a supine blood pressure, taken on 3 different occasions, above 90 mmHg diastolic on each occasion. The diagnosis of essential hypertension was made if laboratory investigation and angiography had excluded secondary forms of hypertension. Subjects with proteinuria over 1.5 g a day, haematuria or abnormalities on urine microscopy were excluded. Subjects with diabetes mellitus were also excluded from the study. The diagnosis of unilateral renal artery stenosis was made if on a Seldinger arteriography or on an arterial digital subtraction angiography a luminal narrowing of more than 70% of the surface was present. Fifteen successive patients were selected in whom a diagnosis of renal artery stenosis was made. The patients were included if their characteristics were in agreement with the protocol as outlined above. The subjects with essential hypertension were also 15 successive patients in whom the diagnosis of essential hypertension was made and whose clinical data matched the study terms. In all subjects
antihypertensive medication and a sodium-restricted diet were discontinued at least 2 weeks before the urine sampling. In the setting of the outpatient department it is hardly possible to bring subjects into a fixed sodium balance. We assumed that by taking an unlimited sodium diet the patients would reach a steady state with regard to their salt status. All other medication was also withheld. Special emphasis was given to prevent the use of cyclo-oxygenase-inhibiting drugs. The patients were asked to refrain from smoking and sexual activity from 24 h before the start of the urine sampling.

Urine was sampled during two successive periods of 24 h because, in case of any collection problem, there would be a second sample. As standard the first of the two samples was used. In 2 cases the ratio of PGE$_2$ and prostaglandin F$_{2\alpha}$, which for this purpose was also measured, was over 0.5, indicating that the sample was contaminated by seminal fluid and therefore the second sample was used [19]. The creatinine content of the urine sample that was used for the study was measured to calculate the endogenous creatinine clearance (ECC). Twenty-four hour urinary sodium content was measured in the same 24-h urine as the prostaglandins or, if this was not feasible, it was measured in a 24-h urine sample of the same week in which the 24-h urine for the prostaglandin measurements was taken.

The levels of PGE$_2$, PGF$_{2\alpha}$, 6-keto-PGF$_{1\alpha}$ and TxB$_2$ were determined by radioimmunoassays, according to procedures described previously [20,21]. After 10 consecutive assays the PGE$_2$ determinations showed 6.4 and 15%, the PGF$_{2\alpha}$ assay 5.3 and 11%, the 6-keto-PGF$_{1\alpha}$ assay 7.3 and 9.6%, and the TxB$_2$ assay 8.1 and 12.5% intra- and interassay variability, respectively.

To relate prostaglandin excretion to functional renal mass, 24-h urinary prostaglandin metabolite excretion was indexed to the 24-h creatinine content of the same sample. Plasma renin activity (PRA) was measured under baseline conditions, meaning that all antihypertensive medications were stopped for at least 2 weeks. After blood for baseline PRA was taken, patients took an oral dose of 25 mg of captopril and 60 min after that blood for captopril-stimulated PRA was drawn. During this procedure the patients remained in the supine position.

The features of gender, age, body mass index (body weight in kilograms divided by the square of the length in metres), endogenous creatinine clearance, PRA, 24-h urinary sodium content, smoking habits and blood pressure levels were compared as were the 24-h urinary PGE$_2$, 6-keto-PGF$_{1\alpha}$ and thromboxane B$_2$ excretion and the prostaglandin levels indexed to 24-h creatinine.

### Statistical analysis

Patient characteristics among the groups were compared with Wilcoxon's rank sum test apart from the gender and the numbers of smokers, who were compared with Fisher's exact test. The 24-h urinary prostaglandin and prostaglandin metabolite excretion were also compared by Wilcoxon's rank sum test. Outcomes with a p-value of less than 5% were regarded as significant. All tests were performed two-sided. In a forward stepwise logistic regression procedure the independent relation of age, ECC, body mass index, smoking, systolic and diastolic blood pressure and the diagnosis of essential hypertension and renal artery stenosis to the prostaglandin and

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical characteristics of patients with essential hypertension (EH) ($n = 15$) and patients with renal artery stenosis (RAS) ($n = 15$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender (F/M)</td>
<td>EH: 5/10 RAS: 3/12</td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>EH: 45 (20–63) RAS: 53 (21–74)</td>
</tr>
<tr>
<td>Body mass index (kg/m$^2$)</td>
<td>EH: 25 (21–33) RAS: 25 (21–31)</td>
</tr>
<tr>
<td>Urinary Na (mmol/24 h)</td>
<td>EH: 155 (40–313) RAS: 154 (40–200)</td>
</tr>
<tr>
<td>ECC (ml/min)</td>
<td>EH: 94 (64–141) RAS: 82 (29–124)</td>
</tr>
<tr>
<td>No. of smokers (%)</td>
<td>EH: 1 (6%) RAS: 9 (60%)</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>EH: 170 (140–240) RAS: 184 (144–220)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>EH: 108 (80–150) RAS: 110 (80–130)</td>
</tr>
</tbody>
</table>

Median and (between brackets) the range are indicated, unless indicated otherwise. ECC = endogenous creatinine clearance. ** Indicates significant difference between EH and RAS, $p < 0.01$. 
Table 2
Urinary prostaglandin metabolite excretion and plasma renin activity in essential hypertensives (EH) (n = 15) and patients with hypertension and renal artery stenosis RAS (n = 15)

<table>
<thead>
<tr>
<th></th>
<th>EH</th>
<th>RAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-Ketoprostaglandin F₁α (nmol/24 h)</td>
<td>1.9 (0.54–3.6)* *</td>
<td>1.1 (0.28–2.5)</td>
</tr>
<tr>
<td>Prostaglandin E₂ (nmol/24 h)</td>
<td>0.87 (0.09–13)</td>
<td>0.8 (0.23–5.3)</td>
</tr>
<tr>
<td>Thromboxane B₂ (nmol/24 h)</td>
<td>1.2 (0.3–2.1)</td>
<td>1.2 (0.42–2.7)</td>
</tr>
</tbody>
</table>

Prostaglandin metabolite excretion (nmol / l / 24 h) indexed to urinary creatinine excretion (mmol / l / 24 h)

<table>
<thead>
<tr>
<th></th>
<th>EH</th>
<th>RAS</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-Ketoprostaglandin F₁α</td>
<td>0.13 (0.07–0.28) *</td>
<td>0.08 (0.04–0.27)</td>
</tr>
<tr>
<td>Prostaglandin E₂</td>
<td>0.05 (0.01–1.02)</td>
<td>0.06 (0.02–0.45)</td>
</tr>
<tr>
<td>Thromboxane B₂</td>
<td>0.08 (0.04–0.21)</td>
<td>0.12 (0.03–0.36)</td>
</tr>
</tbody>
</table>

Plasma renin activity (nmol / l / h)

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>After 25 mg of captopril</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.87 (0.1–3.96)</td>
<td>1.9 (0.4–7.7)</td>
</tr>
<tr>
<td></td>
<td>1.24 (0.1–2.89)* *</td>
<td>9.8 (0.1–51.1)</td>
</tr>
</tbody>
</table>

Given are Medians and between brackets ranges. * * Indicates difference p < 0.01; * indicates difference p < 0.05.

prostaglandin metabolite excretion were analysed.

3. Results

The study included 15 patients with essential hypertension and 15 with unilateral RAS. All patients with RAS had atherosclerotic vascular narrowing as evidenced by angiography.

The number of smokers was significantly higher in the patients with RAS (Table 1). The clinical features of gender, age and body mass index were not significantly different among the groups (Table 1). Twenty-four hour urinary sodium excretion was also not significantly different: median 155 (range 40–313) mmol/24 h in the EH group and 154 (40–200) mmol/24 h in the group with RAS (Table 1). Blood pressure in the essential hypertensives and in those with RAS was not significantly different: 170 (140–240)/108 (80–150) and 184 (144–220)/110 (80–130) mmHg, respectively (Table 1). Baseline PRA was 0.87 (0.1–3.96) nmol/l/h in the EH group and 1.9 (0.4–7.7) nmol/l/h in the RAS group, which was not significantly different (Table 2). The captopril-stimulated PRA was significantly higher in the patients with RAS: 9.8 (0.1–51.1) vs. 1.24 (0.1–2.89) nmol/l/h in the EH group (Table 2). In the group of essential hypertensives there was no significant rise in PRA after captopril, but in the patients with a RAS the rise in PRA after captopril was significant (Table 2). Twenty-four hours 6-keto-prostaglandin F₁α excretion was with a median of 1.1 (0.28–2.5) nmol/24 h significantly lower in the patients with RAS as compared with the value of 1.9 (0.54–3.6) nmol/24 h in the essential hypertensives (Table 2). Also indexed to the 24-h creatinine excretion, 24-h 6-ketoprostaglandin F₁α excretion was significantly lower in the patients with RAS; 0.08 (0.04–0.28) vs. 0.13 (0.07–0.27) nmol/mmol (Table 2). Regarding the other prostaglandins and prostaglandin metabolites, no significant differences in the values for the 24-h urinary excretion among the groups were detected.

In the forward stepwise logistic procedure the diagnosis of renal artery stenosis showed a significant relationship to the 24-h 6-ketoprostaglandin F₁α urinary excretion ($r^2 = 0.30$, $p < 0.01$). Furthermore, PGB₂ excretion showed a significant relation to smoking ($r^2 = 0.22$, $p < 0.01$).

4. Discussion

Because renovascular hypertension can be treated successfully in a large number of patients, it is worthwhile to try to identify those with this condition among the general hypertensive population [22–25]. However, the certain diagnosis of a renal artery stenosis can only be made by an-
giography [22–25]. In view of the low prevalence of renal artery stenosis in the hypertensive population, angiography, because of its invasive nature and cost, cannot be used as a screening procedure. Therefore a sensitive and reliable non-invasive screening procedure that can detect this condition would be an important tool in clinical practice.

A number of studies have shown that in the case of stimulation of the renin–angiotensin system, especially as a result of renal ischaemia, renal eicosanoid production rises [1–9]. Since a significant renal artery stenosis is a situation of renal ischaemia, it might be expected that this condition results in an elevated renal prostaglandin production. Thus, by assessing renal eicosanoid production, which can be done reliably and non-invasively by measuring urinary prostaglandin and prostaglandin metabolite excretion, the presence of a renal artery stenosis should be detectable if the concomitant hypertension is related to the stenosis and therefore renin–angiotensin-mediated.

The patients with a RAS in the present study showed a significant rise in PRA after the administration of captopril, indicating the renin dependency of their renal haemodynamic regulation, as compared with the absence of such a rise in the essential hypertensive patients.

However, the expected higher levels of urinary prostaglandin excretion were not present in the group with RAS. On the contrary, we found a significantly lower 6-keto-prostaglandin F1α excretion in the patients with a unilateral RAS.

How can these results be explained? One difference between the groups is the number of smokers, which was higher in the patients with RAS. To exclude as much as possible the acute effects of smoking, the participants were asked to refrain from smoking for at least 24 h. Most of the clinical studies concerning eicosanoid production do not mention smoking habits of the studied population and in one study smoking discontinuation of 3 h was considered long enough to minimize its effects on eicosanoid levels [26]. Creating a group of non-smoking patients with RAS would have introduced considerable bias, as atherosclerotic renal artery disease is strongly linked to smoking. Smoking causes a rise in platelet-derived prostaglandin production, mainly of TxA2 and, probably vessel-wall-derived, prostaglandin I2 as measured by the elevated urinary excretion of their metabolites TxB2 and 6-ketoprostaglandin F1α [27,28]. We could not substantiate such a rise because the levels of TxB2 were comparable in the two groups, although TxB2 excretion showed a relation to smoking. The level of PGI2 was lower in the group of RAS with the highest number of smokers. Because smoking would have enhanced the differences expected, it seems very unlikely that the difference in smoking could have substantially influenced the results of prostaglandin I2 and of 6-ketoprostaglandin F1α excretion. Apart from TxB2, the other prostanoic excretions also did not show a relation to smoking.

Other causes of diminished 6-ketoprostaglandin F1α excretion might be found in a difference in functional renal mass or the presence of parenchymal renal disease. A severely diminished renal mass can cause a decline in renal prostaglandin production because renal tissue produces the renal prostanoids. Renal parenchymal diseases can give rise to various changes in renal prostaglandin production including an increase or decrease of the excretion depending on the offending condition [29–32]. However, between the two groups the endogenous creatinine clearance was not statistically different, indicating a comparable renal functional mass, and also the eicosanoid excretion indexed to creatinine excretion showed a lower 6-ketoprostaglandin F1α excretion in the patients with a RAS, which makes a diminished functional renal mass unlikely as the cause of the different findings. As we excluded patients with parenchymal renal disease, the difference in eicosanoid excretion can also not be explained by possible renal diseases.

What other explanation for the results of the present study might be valid? In a recent study of renal vein prostaglandin concentrations before and after cyclo-oxygenase inhibition with aspirin DL-lysine it was found that the level of prostaglandins in the veins of the stenotic kidney was increased in relation to the other kidney and declined within 30 mins after intravenous aspirin
DL-lysine [3,4]. Although the level of the prostaglandins in the aorta was also higher than in patients with essential hypertension and low renin, they were not lower than in essential hypertensive patients with high renin, and as renal flow was not measured it remains unclear if renal prostaglandin production was in fact increased. If the concentration changes were caused by changes in flow, it is clear that such changes cannot be detected by differences in 24-hour urinary eicosanoid excretion.

As there were no significant differences in baseline PRA between our patients with essential hypertension and those with RAS, it might well be that the only differences present in such patients are differences in prostaglandin concentrations between the affected and non-affected renal veins.

To elucidate this problem, both hormone concentrations and renal blood flow have to be studied. Probably then an explanation can be given for the absence of the expected differences in prostaglandin excretion in the present study.

Due to the overlap in individual values, 6-ketoprostaglandin F1α excretion could also not be used to make a diagnostic differentiation between the subjects. Thus, by measuring the concentrations of renal prostaglandin or prostaglandin metabolites in the urine, no distinction could be made between essential hypertension and hypertension with renal artery stenosis.

References


